NAMS NewAmsterdam Pharma Co N.V.
Nasdaq · SEC CIK 1936258 · EDGAR
- Bought, last 12 months
- $226.5K 1 purchases by 1 insiders
- Sold, last 12 months
- $62.00M 19 sales by 6 insiders
- Filings on record
- 108 since 2024-01-03, latest 2026-09-15 16:30
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| Davidson Michael H. | CEO, Dir | $226.5K | $25.33M |
| Kooij Louise Frederika | CAO | — | $16.75M |
| Kastelein Johannes Jacob Pieter | CSO, Dir | — | $14.26M |
| Somaiya Mayur Ian | CFO | — | $3.43M |
| LANGE LOUIS G | Dir | — | $2.19M |
| Smither John W | Dir | — | $40.5K |
| Gunning Robert William | VP, Ctrl | — | — |
| van der Kamp Hilde Johanna | Dir | — | — |
| McKenna Mark C. | Dir | — | — |
| Gulfo Adele M. | Dir | — | — |
Transactions 122
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-01-07 | 2025-01-07 | NAMS | Somaiya Mayur Ian | CFO | A - Grant | — | +38.0K | 38.0K | New | — | |
| 2025-01-07 | 2025-01-07 | NAMS | Kling Douglas F | COO | A - Grant | — | +44.0K | 44.0K | New | — | |
| 2025-01-07 | 2025-01-07 | NAMS | Audet Juliette Berangere | Chief Business Off | A - Grant | — | +14.0K | 15.1K | +1,268% | — | |
| TI | 2025-01-02 | 2024-12-30 | NAMS | ForGrowth NAP B.V. | 10% | S - Sale | $25.54 | -29.8K | 10.66M | -0.3% | -$762.3K |
| MTI | 2024-12-30 | 2024-12-26+ | NAMS | Forbion Capital Fund IV Cooperatief U.A. | 10% | S - Sale | $25.98 | -74.9K | 10.73M | -0.7% | -$1.95M |
| MTI | 2024-12-26 | 2024-12-20+ | NAMS | Forbion IV Management B.V. | 10% | S - Sale | $25.58 | -91.1K | 10.76M | -0.8% | -$2.33M |
| MTI | 2024-12-20 | 2024-12-18+ | NAMS | ForGrowth NAP B.V. | 10% | S - Sale | $25.87 | -157.2K | 10.91M | -1% | -$4.07M |
| MTI | 2024-12-18 | 2024-12-16+ | NAMS | Forbion IV Management B.V. | 10% | S - Sale | $25.95 | -115.5K | 11.12M | -1% | -$3.00M |
| MTI | 2024-12-16 | 2024-12-12+ | NAMS | Forbion IV Management B.V. | 10% | S - Sale | $25.34 | -191.8K | 11.18M | -2% | -$4.86M |
| MTI | 2024-12-12 | 2024-12-10+ | NAMS | Forbion Growth Management B.V. | 10% | S - Sale | $25.40 | -462.3K | 11.52M | -4% | -$11.74M |
| MTI | 2024-11-19 | 2024-11-15+ | NAMS | ForGrowth NAP B.V. | 10% | S - Sale | $25.07 | -41.8K | 11.78M | -0.4% | -$1.05M |
| MTI | 2024-11-15 | 2024-11-13+ | NAMS | Forbion Capital Fund IV Cooperatief U.A. | 10% | S - Sale | $25.01 | -10.9K | 11.83M | -0.1% | -$272.5K |
| D | 2024-10-01 | 2024-09-27 | NAMS | Kooij Louise Frederika | CAO | M - OptEx | — | +45.0K | 45.0K | New | — |
| D | 2024-10-01 | 2024-10-01 | NAMS | Kooij Louise Frederika | CAO | S - Sale+OE | $15.72 | -45.0K | 0 | -100% | -$707.4K |
| 2024-09-30 | 2024-09-26 | NAMS | Audet Juliette Berangere | Chief Business Off | P - Purchase | $15.70 | +1,104 | 1,104 | New | +$17.3K | |
| 2024-08-22 | 2024-08-20 | NAMS | Davidson Michael H. | CEO, Dir | P - Purchase | $16.27 | +5,000 | 209.8K | +2% | +$81.3K | |
| 2024-06-24 | 2024-06-20 | NAMS | Davidson Michael H. | CEO, Dir | P - Purchase | $17.26 | +5,000 | 204.8K | +3% | +$86.3K | |
| I | 2024-03-28 | 2024-03-26 | NAMS | Topper James N | Dir | P - Purchase | $21.50 | +8,429 | 3.01M | +0.3% | +$181.2K |
| DI | 2024-03-27 | 2024-03-26 | NAMS | Kastelein Johannes Jacob Pieter | CSO, Dir | S - Sale+OE | $21.50 | -190.5K | 0 | -100% | -$4.10M |
| DI | 2024-03-27 | 2024-03-26 | NAMS | Kastelein Johannes Jacob Pieter | CSO, Dir | F - Tax | $22.72 | -11.2K | 190.5K | -6% | -$254.4K |
| DI | 2024-03-27 | 2024-03-26 | NAMS | Kastelein Johannes Jacob Pieter | CSO, Dir | M - OptEx | — | +201.7K | 201.7K | New | — |
| I | 2024-02-21 | 2024-02-13 | NAMS | LANGE LOUIS G | Dir | P - Purchase | $19.00 | +5,000 | 24.9K | +25% | +$95.0K |
Purchase Sale Sale after option exercise All abbreviations